2026 Global: Amyotrophic Lateral Sclerosis (Als) Treatment -Competitive Review (2032) report
Description
The 2026 Global: Amyotrophic Lateral Sclerosis (Als) Treatment -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for amyotrophic lateral sclerosis (als) treatment by geography and historical trend. The scope of the report extends to sizing of the amyotrophic lateral sclerosis (als) treatment market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The landscape of Amyotrophic Lateral Sclerosis (ALS) treatment features ten major companies driving innovation through approved therapies and advanced pipelines. Mitsubishi Tanabe Pharma leads with Radicava (edaravone), the top revenue-generating drug projected at USD 923 million, targeting oxidative stress in sporadic ALS cases. Biogen, in partnership with Ionis Pharmaceuticals, markets Qalsody (tofersen), an antisense oligonucleotide (ASO) approved in 2023 for SOD1-mutated ALS, demonstrating disease reversal in some patients. Amylyx Pharmaceuticals developed Relyvrio (AMX0035), a combination therapy that slowed functional decline in Phase II trials despite later challenges, alongside new ASO AMX0114 with Fast Track status. BrainStorm Cell Therapeutics advances NurOwn, an autologous stem cell therapy cleared for Phase 3b trials in 2025, focusing on biomarkers and survival. These established players control nearly 45% of the market, emphasizing symptomatic relief and mutation-specific interventions.
Emerging biotechs are accelerating ALS pipelines with novel modalities amid a market growing from USD 0.9 billion in 2025 to USD 1.21 billion by 2030. Prilenia Therapeutics prepares Phase 3 for pridopidine, a Sigma-1 receptor agonist showing promise in HEALEY trials for neuroprotection. NeuroSense Therapeutics finalizes Phase 3 protocol for PrimeC, a ciprofloxacin-celecoxib combo that slowed progression and boosted survival in Phase IIb. AB Science develops masitinib, a tyrosine kinase inhibitor in late-stage trials targeting neuroinflammation. Clene Nanomedicine advances CNM-Au8, a gold nanocrystal reducing neuroinflammation per HEALEY data. Annexon Biosciences pursues complement inhibitors to halt neurodegeneration, featured in multiple promising pipelines. These firms leverage platform trials and orphan designations to address unmet needs in 90-95% sporadic cases.
Recent advancements signal a renaissance, with gene therapies and degraders poised to expand options. Cytokinetics and MediciNova contribute ibudilast for Phase III neuroprotection. Trace Neuroscience, launched in 2024 with $101 million, targets UNC13A via ASOs. Collaborations like Alchemab-Eli Lilly and regulatory nods for Klotho Neurosciences' KLTO-202 underscore momentum toward precision medicine. Despite setbacks like Relyvrio's withdrawal, targeted therapies for C9ORF72 and FUS mutations, including Ulefnersen (Ionis), highlight a shift from symptomatic care. Multidisciplinary clinics and big-pharma alliances, such as Eli Lilly's QurAlis acquisition, propel growth, offering hope for extended survival.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for amyotrophic lateral sclerosis (als) treatment by geography and historical trend. The scope of the report extends to sizing of the amyotrophic lateral sclerosis (als) treatment market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The landscape of Amyotrophic Lateral Sclerosis (ALS) treatment features ten major companies driving innovation through approved therapies and advanced pipelines. Mitsubishi Tanabe Pharma leads with Radicava (edaravone), the top revenue-generating drug projected at USD 923 million, targeting oxidative stress in sporadic ALS cases. Biogen, in partnership with Ionis Pharmaceuticals, markets Qalsody (tofersen), an antisense oligonucleotide (ASO) approved in 2023 for SOD1-mutated ALS, demonstrating disease reversal in some patients. Amylyx Pharmaceuticals developed Relyvrio (AMX0035), a combination therapy that slowed functional decline in Phase II trials despite later challenges, alongside new ASO AMX0114 with Fast Track status. BrainStorm Cell Therapeutics advances NurOwn, an autologous stem cell therapy cleared for Phase 3b trials in 2025, focusing on biomarkers and survival. These established players control nearly 45% of the market, emphasizing symptomatic relief and mutation-specific interventions.
Emerging biotechs are accelerating ALS pipelines with novel modalities amid a market growing from USD 0.9 billion in 2025 to USD 1.21 billion by 2030. Prilenia Therapeutics prepares Phase 3 for pridopidine, a Sigma-1 receptor agonist showing promise in HEALEY trials for neuroprotection. NeuroSense Therapeutics finalizes Phase 3 protocol for PrimeC, a ciprofloxacin-celecoxib combo that slowed progression and boosted survival in Phase IIb. AB Science develops masitinib, a tyrosine kinase inhibitor in late-stage trials targeting neuroinflammation. Clene Nanomedicine advances CNM-Au8, a gold nanocrystal reducing neuroinflammation per HEALEY data. Annexon Biosciences pursues complement inhibitors to halt neurodegeneration, featured in multiple promising pipelines. These firms leverage platform trials and orphan designations to address unmet needs in 90-95% sporadic cases.
Recent advancements signal a renaissance, with gene therapies and degraders poised to expand options. Cytokinetics and MediciNova contribute ibudilast for Phase III neuroprotection. Trace Neuroscience, launched in 2024 with $101 million, targets UNC13A via ASOs. Collaborations like Alchemab-Eli Lilly and regulatory nods for Klotho Neurosciences' KLTO-202 underscore momentum toward precision medicine. Despite setbacks like Relyvrio's withdrawal, targeted therapies for C9ORF72 and FUS mutations, including Ulefnersen (Ionis), highlight a shift from symptomatic care. Multidisciplinary clinics and big-pharma alliances, such as Eli Lilly's QurAlis acquisition, propel growth, offering hope for extended survival.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.